Bioorthogonal Cleavage and Exchange of Major Histocompatibility Complex Ligands by Employing Azobenzene‐Containing Peptides

Choo, Joanna Ai Ling; Thong, Sock Yue; Yap, Jiawei; Esch, Wim J. E. van; Raida, Manfred; Meijers, Rob; Lescar, Julien; Verhelst, Steven H. L.; Grotenbreg, Gijsbert M.

doi:10.1002/anie.201406295

Cited by 30 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HLA-A0201 was selected for docking and the molecular structure was downloaded from the RCSB Protein Data Bank (). The structure 4UQ3 of this database was the crystal structure of HLA-A0201 in complex with an azobenzene-containing peptide [39]. HLA-A0201 was simplified from this structure, and the water molecule was also removed.…”

Section: Methodsmentioning

confidence: 99%

In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein

Zheng

Lin

Wang

et al. 2017

Viruses

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection has persisted as a major public health problem due to the lack of an effective treatment for those chronically infected. Therapeutic vaccination holds promise, and targeting HBV polymerase is pivotal for viral eradication. In this research, a computational approach was employed to predict suitable HBV polymerase targeting multi-peptides for vaccine candidate selection. We then performed in-depth computational analysis to evaluate the predicted epitopes’ immunogenicity, conservation, population coverage, and toxicity. Lastly, molecular docking and MHC-peptide complex stabilization assay were utilized to determine the binding energy and affinity of epitopes to the HLA-A0201 molecule. Criteria-based analysis provided four predicted epitopes, RVTGGVFLV, VSIPWTHKV, YMDDVVLGA and HLYSHPIIL. Assay results indicated the lowest binding energy and high affinity to the HLA-A0201 molecule for epitopes VSIPWTHKV and YMDDVVLGA and epitopes RVTGGVFLV and VSIPWTHKV, respectively. Regions 307 to 320 and 377 to 387 were considered to have the highest probability to be involved in B cell epitopes. The T cell and B cell epitopes identified in this study are promising targets for an epitope-focused, peptide-based HBV vaccine, and provide insight into HBV-induced immune response.

show abstract

Section: Methodsmentioning

confidence: 99%

In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein

Zheng

Lin

Wang

et al. 2017

Viruses

View full text Add to dashboard Cite

show abstract

“…24 Biotinylated peptide-MHC (pMHC) complexes were then added into streptavidin-coated enzyme-linked immunosorbent assay (ELISA) wells in quadruplicates. TCR-like mAbs were serially diluted and incubated with the pMHC complexes before detection with horseradish peroxidase-conjugated goat anti-mouse secondary antibody (ThermoScientific).…”

Section: Materials and Methods Pmhc Elisamentioning

confidence: 99%

Targeting Epstein-Barr virus–transformed B lymphoblastoid cells using antibodies with T-cell receptor–like specificities

Lai¹,

Tan

Too³

et al. 2016

Blood

View full text Add to dashboard Cite

• Anti-EBV TCR-like monoclonal antibodies reduce BLCLs tumor load in vivo.• Anti-EBV TCR-like monoclonal antibodies mediate phagocytosis of BLCLs by macrophages.Epstein-Barr virus (EBV) is an oncovirus associated with several human malignancies including posttransplant lymphoproliferative disease in immunosuppressed patients. We show here that anti-EBV T-cell receptor-like monoclonal antibodies (TCR-like mAbs) E1, L1, and L2 bound to their respective HLA-A*0201-restricted EBV peptides EBNA1 562-570 , LMP1 [125][126][127][128][129][130][131][132][133] , and LMP2A 426-434 with high affinities and specificities. These mAbs recognized endogenously presented targets on EBV B lymphoblastoid cell lines (BLCLs), but not peripheral blood mononuclear cells, from which they were derived. Furthermore, these mAbs displayed similar binding activities on several BLCLs, despite inherent heterogeneity between different donor samples. A single weekly administration of the naked mAbs reduced splenomegaly, liver tumor spots, and tumor burden in BLCL-engrafted immunodeficient NOD-SCID/Il2rg 2/2 mice. In particular, mice that were treated with the E1 mAb displayed a delayed weight loss and significantly prolonged survival. In vitro, these TCR-like mAbs induced early apoptosis of BLCLs, thereby enhancing their Fc-dependent phagocytic uptake by macrophages. These data provide evidence for TCR-like mAbs as potential therapeutic modalities to target EBV-associated diseases. (Blood. 2016;128(10):1396-1407

show abstract

“…The grid box was then allocated properly in the target to include the active residue in the center. The default docking algorithms were set in accordance with standard docking protocol [30] . Finally, ten independent docking runs were carried out for each ligand and results were retrieved as binding energies.…”

Section: Ligand Preparationmentioning

confidence: 99%

Epitope - based peptide vaccine against glycoprotein GPC precursor of Lujo virus using immunoinformatics approaches

Mohammed¹,

Elkhalifa

Elamin

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundLujo virus (LUJV) is a highly fatal human pathogen belonging to the Arenaviridae family. Lujo virus causes viral hemorrhagic fever (VHF). An In silico molecular docking was performed on the GPC domain of Lujo virus in complex with the first CUB domain of neuropilin-2.The aim of this study is to predict effective epitope-based vaccine against glycoprotein GPC precursor of Lujo virus using immunoinformatics approaches.Methods and Materialsglycoprotein GPC precursor of Lujo virus Sequence was retrieved from NCBI. Different prediction tools were used to analyze the nominee’s epitopes in BepiPred-2.0: Sequential B-Cell Epitope Predictor for B-cell, T-cell MHC class II & I. Then the proposed peptides were docked using Autodock 4.0 software program.Results and ConclusionsThe proposed and promising peptides FWYLNHTKL and YMFSVTLCI shows a very strong binding affinity to MHC class I & II alleles with high population coverage for the world, South Africa and Sudan. This indicates a strong potential to formulate a new vaccine, especially with the peptide YMFSVTLCI which is likely to be the first proposed epitope-based vaccine against glycoprotein GPC of Lujo virus. This study recommends an in-vivo assessment for the most promising peptides especially FWYLNHTKL, YMFSVTLCI and LPCPKPHRLR.

show abstract

Bioorthogonal Cleavage and Exchange of Major Histocompatibility Complex Ligands by Employing Azobenzene‐Containing Peptides

Cited by 30 publications

References 25 publications

In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein

In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein

Targeting Epstein-Barr virus–transformed B lymphoblastoid cells using antibodies with T-cell receptor–like specificities

Epitope - based peptide vaccine against glycoprotein GPC precursor of Lujo virus using immunoinformatics approaches

Contact Info

Product

Resources

About